
Clinical Trials - September 22, 2014
Umecrine Mood announces positive results
The company has announced positive results from an exploratory Phase I/II study with UC1010 in premenstrual dysphoric disorder (PMDD). On September 19 Umecrine Mood announced the final results from an exploratory randomized Phase I/II study with its candidate drug UC1010 in patients with PMDD. The company states that the results show a statistically significant improvement of […]

Clinical Trials - June 13, 2014
Negative outcome in PMDD study
Umecrine’s drug candidate for PMDD treatment did not show any effect compared to placebo according to the results from a phase II study. In an exploratory double blind, randomized multicenter study, 120 patients with PMDD received, during one menstrual cycle, either placebo or one of two different doses of the drug candidate UC1010, a GABA-A […]

Clinical Trials - January 8, 2014
Patient recruitment completed in Phase I/II study of Umecrine Mood’s candidate drug
Umecrine Mood AB had announced that patient recruitment for the ongoing phase I/II study with UC1010 for the treatment of severe premenstrual symptoms (PMDD) has been completed. Umecrine Mood is part of the Karolinska Development portfolio. ”About half of the patients planned for the study have completed the treatment. The remaining participants are currently in […]